Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis

Jeanine Flanigan(Sanden (Japan)), GH Lyman(Duke University), Marion Schauf, Lamees Almuallem(EVERSANA (Canada)), A Zhou(EVERSANA (Canada)), Mike Tindal(Sanden (Japan)), Edward Li(Sanden (Japan)), Sarah Kane(EVERSANA (Canada)), Fatemeh Mirzayeh Fashami(EVERSANA (Canada))
PharmacoEconomics - Open
April 14, 2026
Cited by 1


Related Papers